Skip to main content

Dr. Alexandre E. Malek, MD

Infectious Disease (Infectious Disease Physician)

  • Medicare participating

At a glance

Years since graduation
14
In the NPI registry since
2018
Medicare patients seen, 2024
106

Licensed in Texas since 2026, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2018Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Infectious Disease Physician primary
    LA license 328253 · TX license W6301 (first issued 2026; active)
  • Internal Medicine Physician
    LA license 328253

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Infectious Disease per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
106
Services billed
394
Patients’ average age
64
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes22673
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes6816
Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes6261
Established patient office or other outpatient visit, 30-39 minutes5533
Established patient office or other outpatient visit, 20-29 minutes2114
Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes1515

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Biktarvy (bictegrav/emtricit/tenofov ala)168
Juluca (dolutegravir/rilpivirine)59
Sulfamethoxazole-Trimethoprim (sulfamethoxazole/trimethoprim)
Other prescribers in Houston, TX
47
Tivicay (dolutegravir sodium)47
Prezcobix (darunavir/cobicistat)37
Dovato (dolutegravir sodium/lamivudine)34
Odefsey (emtricitab/rilpiviri/tenof ala)26
Doxycycline Hyclate
Other prescribers in Houston, TX
24
Valacyclovir (valacyclovir hcl)
Other prescribers in Houston, TX
22
Pifeltro (doravirine)19

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 13 companies reported 68 payments worth $1,356 in total to this clinician.

By company
AbbVie Inc.$234
Merck Sharp & Dohme LLC$202
Viiv Healthcare Company$198
Paratek Pharmaceuticals, Inc.$176
Gilead Sciences, Inc.$171
Shionogi Inc$68.41
Astellas Pharma US Inc$63.40
Insmed, Inc.$58.72
By type
Food and Beverage$1,328
Education$28.23

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Sep 24, 2025Insmed, Inc.
Sep 24, 2025
Education
Brinsupri; Brinsupri · Respiratory · in-kind
$17.38
May 19, 2025Merck Sharp & Dohme LLC
May 19, 2025
Education
ZERBAXA · INFECTIOUS DISEASE · in-kind
$10.85

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Texas →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $45,606 in research payments for these studies, mostly to the institutions running them.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Infectious Disease clinicians in Houston

Sources

NPI registry (CMS NPPES, November 2026; record last updated June 17, 2026), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1184122731. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.